Details for Patent: 12,297,189

« Back to Dashboard

Which drugs does patent 12,297,189 protect, and when does it expire?

Patent 12,297,189 protects TRYVIO and is included in one NDA.

This patent has seventy-four patent family members in twenty-nine countries.

Summary for Patent: 12,297,189

Title:	Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
Abstract:	The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.
Inventor(s):	Martin Bolli, Markus von Raumer
Assignee:	Actelion Pharmaceuticals Ltd , Idorsia Pharmaceuticals Ltd
Application Number:	US18/319,402
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Dosage form;

Drugs Protected by US Patent 12,297,189

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes			Y

International Family Members for US Patent 12,297,189

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017400276
Australia	2018225309
Brazil	112019017644
Brazil	112019017658
Canada	3053991
Canada	3053994
Chile	2019002464